CNS Pharmaceuticals, Inc.
CNSP evidence brief
What we can confirm
- BioSniper Score:
- 5.8 / 10
- Market Cap:
- $8.5M
- Lead Asset:
- TPI 287 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for CNSP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CNSP
CNS Pharmaceuticals is a clinical-stage biotechnology company pivoting from a single-asset focus to a diversified pipeline of neurology and oncology therapies, with a strengthened cash position following a $22.5 million financing in mid-2026.
Key risk: No product revenue
BioSniper Score
Based on 4 of 6 signals
Market Cap
$8.5M
Cash Runway
—
Lead Asset
TPI 287 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for CNS Pharmaceuticals, Inc..
CNS Pharmaceuticals is a clinical-stage biotechnology company pivoting from a single-asset focus to a diversified pipeline of neurology and oncology therapies, with a strengthened cash position following a $22.5 million financing in mid-2026.
- Cash & equivalents of $20.0M as of 2026-06-30 [sec].
- Net loss of $2.6M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $18.2M as of 2026-06-30 [sec].
- Announced a new corporate strategy in March 2026 to build a high-value pipeline in neurology and oncology [sec_mda · as of 2026-03-31].
- Completed an oversubscribed $22.5 million financing, extending operating runway [news · published 2026-08-12].
What works
- Strengthened balance sheet with approximately $20.0 million cash position following a $22.5 million financing [news · published 2026-08-12].
- Executing a strategic pivot from a single-asset focus to a diversified pipeline in neurology and oncology, leveraging a disciplined asset evaluation approach [sec_mda · as of 2026-03-31].
- Management team has multi-functional experience across high-value therapeutic areas [sec_mda · as of 2026-03-31].
What to weigh
- No revenues from product sales to date; expects to continue incurring losses for the foreseeable future [sec_mda · as of 2026-03-31].
- Cash runway estimated only into the third quarter of 2026 as of March 2026, with no committed additional financing [sec_mda · as of 2026-03-31].
- Significant capital needed to in-license and develop new assets; future funding requirements are uncertain [sec_mda · as of 2026-03-31].
From the filings
Quoted directly from source documents.
Cash position and financing
“Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing”
News · August 12, 2026
Strategic pivot announcement
“On March 11, 2026, we announced a new corporate growth strategy focused on building a high-value pipeline in neurology and oncology.”
SEC MD&A · March 31, 2026
No product revenues and expected losses
“We have not generated any revenues from product sales. We expect to continue to incur losses for the foreseeable future”
SEC MD&A · March 31, 2026
Cash runway estimate
“We estimate that we have sufficient capital to fund operations into the third quarter of 2026.”
SEC MD&A · March 31, 2026
Risks & what to watch (3)›
Key risks
- No product revenue — Company has not generated any revenues from product sales and expects continued losses [sec_mda · as of 2026-03-31].
- Financing uncertainty
- Cash runway limited — As of March 2026, cash was expected to fund operations only into Q3 2026 [sec_mda · as of 2026-03-31].
What to watch
- Ability to secure additional financing beyond the $22.5 million round to extend runway beyond Q3 2026 [sec_mda · as of 2026-03-31].
- Progress in identifying and in-licensing new neurology/oncology assets under the new strategy [sec_mda · as of 2026-03-31].
- Execution of clinical development plans for any newly acquired assets and achievement of near-term milestones [sec_mda · as of 2026-03-31].
Sources: News · SEC MD&A · Generated October 1, 2026 · How we verify sources →
Run CNS Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CNS Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.21 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 4.9%
- Days to cover
- 1.7
- Shares short
- 38,968
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CNSP short interestGovernance
Frequently asked questions
What is the AI investment thesis for CNS Pharmaceuticals, Inc.?
CNS Pharmaceuticals is a clinical-stage biotechnology company pivoting from a single-asset focus to a diversified pipeline of neurology and oncology therapies, with a strengthened cash position following a $22.5 million financing in mid-2026.
What is CNS Pharmaceuticals, Inc.'s lead drug candidate?
CNS Pharmaceuticals, Inc.'s most advanced tracked candidate is TPI 287 (Preclinical) for Glioblastoma multiforme.
Who is the CEO of CNS Pharmaceuticals, Inc.?
Mr. Rami Levin M.B.A. is the chief executive officer of CNS Pharmaceuticals, Inc. (CNSP).
Where is CNS Pharmaceuticals, Inc. headquartered?
CNS Pharmaceuticals, Inc. (CNSP) is headquartered in Houston, TX, United States.
What therapeutic areas does CNS Pharmaceuticals, Inc. focus on?
CNS Pharmaceuticals, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.